| abstract |
The invention discloses a new crystal form of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene III and crystal form IV, and their preparation methods and their medicinal use as a treatment for diabetes, crystal form III is octanol compound which has a more obvious effect on the treatment of diabetes; Preparation of crystal form III by supersaturated precipitation or recrystallization; since octanol itself, as a gap junction blocker, has the effect of reducing diabetic complications, such as the pharmacological effect of anti-myocyte edema and hypertrophy and neuroprotective effect, compared with other crystal forms Generally speaking, crystal form III has a more obvious effect on the treatment of diabetes, especially in the prevention of cardiovascular complications in early diabetic patients. |